Holly Rachael Keir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1051826/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. European Respiratory Journal, 2018, 52, 1800766.	6.7	105
2	Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 2021, 27, 688-699.	30.7	105
3	The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2021, 147, 158-167.	2.9	102
4	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respiratory Medicine,the, 2021, 9, 873-884.	10.7	99
5	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 33-41.	5.6	70
6	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 894-902.	5.6	67
7	The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respiratory Medicine,the, 2021, 9, 885-896.	10.7	63
8	Distinct "Immunoallertypes―of Disease and High Frequencies of Sensitization in Non–Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 842-853.	5.6	57
9	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and riskÂofÂexacerbation. European Respiratory Journal, 2019, 53, 1900303.	6.7	50
10	Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. Respiratory Research, 2020, 21, 166.	3.6	44
11	A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 2021, 57, 2002050.	6.7	44
12	Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. European Respiratory Review, 2022, 31, 210241.	7.1	44
13	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	5.6	43
14	Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 992-1001.	5.6	42
15	Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease–Bronchiectasis Association― American Journal of Respiratory and Critical Care Medicine, 2022, 206, 417-426.	5.6	29
16	CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Research, 2020, 6, 00583-2020.	2.6	19
17	Inhaled Corticosteroids and the Lung Microbiome in COPD. Biomedicines, 2021, 9, 1312.	3.2	18
18	Increased Chitotriosidase Is Associated With Aspergillus and Frequent Exacerbations in South-East Asian Patients With Bronchiectasis, Chest, 2020, 158, 512-522	0.8	15

HOLLY RACHAEL KEIR

#	Article	IF	CITATIONS
19	Profile of the ProAxsis active neutrophil elastase immunoassay for precision medicine in chronic respiratory disease. Expert Review of Molecular Diagnostics, 2017, 17, 875-884.	3.1	10
20	10â€years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. European Respiratory Journal, 2017, 50, 1701582.	6.7	9
21	The past decade in bench research into pulmonary infectious diseases: <scp>W</scp> hat do clinicians need to know?. Respirology, 2017, 22, 1062-1072.	2.3	9
22	High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest, 2022, 161, 40-53.	0.8	8
23	Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease. Chest, 2022, 161, 1180-1191.	0.8	8
24	SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. European Respiratory Journal, 2021, 58, 2101840.	6.7	3
25	Bronchiectasis enters the inflammation era. Respirology, 2022, 27, 488-489.	2.3	3
26	Non-COVID-19 respiratory viral infection. Breathe, 2022, 18, 210151.	1.3	3
27	Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis. European Respiratory Journal, 2021, 58, 2101416.	6.7	2
28	IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD. European Respiratory Journal, 2021, 58, 2102143.	6.7	1
29	Circulating desmosine as a biomarker of azithromycin treatment response: a <i>post hoc</i> analysis of the COLUMBUS randomised controlled trial. ERJ Open Research, 2018, 4, 00136-2018.	2.6	0
30	Early Career Members at the Lung Science Conference and the Sleep and Breathing Conference 2019. Breathe, 2019, 15, 234-240.	1.3	0
31	Highlights of the ERS Lung Science Conference and Sleep and Breathing Conference 2021 and the new ECMC members. Breathe, 2021, 17, 210080.	1.3	0
32	ERS International Congress 2021: highlights from the Respiratory Infections Assembly. ERJ Open Research, 0, , 00642-2021.	2.6	0
33	ERS ECM Awardee 2021, a preview of LSC 2022 and a brief overview of the Respiratory Channel. Breathe, 2021, 17, 210121.	1.3	0